Company

Tenax Therapeutics

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 9, 2026 · PHASE 3 TRIAL

Long-Term Open-Label Extension Study of Oral Levosimendan

ClinicalTrials.gov

This is a Phase 3 open-label extension study with no results posted; it is a registry record describing an ongoing trial designed to assess safety over continued exposure, not efficacy against a comparator.

PreliminaryPulmonary Hypertension Associated With Hfpef TNX-103 Tenax Therapeutics

Reported

Planned enrollment800

Study phasePhase 3

Primary outcome measureIncidence of select AE/SAEs from enrollment…

AUG 19, 2026 · PHASE 3 TRIAL

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

ClinicalTrials.gov

This is a Phase 3 clinical trial currently recruiting with no results posted; it describes a planned study design and endpoints, not evidence of efficacy or safety.

PreliminaryPulmonary Hypertension Associated With Hfpef TNX-103 Tenax Therapeutics

Reported

Planned sample size540

Primary outcome measure6-Minute Walk Distance (6MWD) change at 26…

PhasePHASE 3